Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Alfagaba
- Development stage
- Unknown
- Lead developer
- Med Manor Organics
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Alfagaba is a fixed-dose combination medication manufactured by Med Manor Organics, primarily indicated for the treatment of neuropathic pain, including diabetic neuropathy and peripheral neuropathy. It contains three active ingredients: gabapentin, alpha-lipoic acid, and methylcobalamin. Gabapentin is an anticonvulsant that acts as a ligand for the alpha-2-delta auxiliary subunits of voltage-gated calcium channels, reducing the release of excitatory neurotransmitters and calming overactive nerves. Alpha-lipoic acid is a potent antioxidant and mitochondrial cofactor that helps reduce oxidative stress and protect nerve tissues. Methylcobalamin is an active coenzyme form of vitamin B12 that supports nerve regeneration and myelin sheath synthesis by acting as a cofactor for methionine synthase. Together, these components work synergistically to alleviate neuropathic pain and promote nerve repair.
- Brand names
- AlfagabaAlfagaba 100Alfagaba100Alfagaba-100Alfagaba 300Alfagaba300Alfagaba-300
- Other names
- alpha-lipoic acid + gabapentin + methylcobalamingabapentin + alpha-lipoic acid + methylcobalamingabapentin + methylcobalamin + alpha-lipoic acid
02
Targets
MTR (Methionine synthase)PDH (Pyruvate dehydrogenase complex)CACNA2D1 (Voltage-gated calcium channel subunit alpha2/delta-1)α2δ (Voltage-gated calcium channel alpha-2-delta subunit)
Beyond the preview
Go deeper on Alfagaba.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Alfagaba.